242647 ⎘
Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
#2Tacrolimus for improved treatment of transplant patients
#3Tacrolimus for improved treatment of transplant patients
#4Tacrolimus for improved treatment of transplant patients
#5Solid dispersions comprising tacrolimus
#6Stabilized tacrolimus composition
#7Methods for inhibiting hematopoietic tumor cells with diphtheria tokin-interleukin-3 conjugates
#8Modified release compositions comprising tacrolimus
#9Solid dispersions comprising tacrolimus
#10Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
#11Methods of treating atopic dermatitis with IL-31 monoclonal antibodies
#12Stabilized tacrolimus composition
#13Tacrolimus for improved treatment of transplant patients
#14Modified release compositions comprising tacrolimus
#15Solid dispersions comprising tacrolimus
#16Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
#17IL-31 monoclonal antibodies
#18Alteration of cell membrane for new functions using IL-2 and streptavidin
#19Methods of modulating immunity
#20Method of treating rheumatoid arthritis with an anti-IL-6R antibody
#21Modulation of NKG2D for prolonging survival of a hematopoietic graft
#22Polynucleotides encoding IL-31 monoclonal antibodies
#23Modified release compositions comprising tacrolimus
#24Modified release compositions comprising tacrolimus
#25Modified release compositions comprising tacrolimus
#26STABILIZED TACROLIMUS COMPOSITION
#27Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof
#28Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
#29Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
#30TNF-alpha ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE
#31CCI-779 concentrate formulations
#32TNF-A and TWEAK dual antagonist for the prophylaxis and treatment of autoimmune diseases
#33Human antibodies that bind human interleukin-12
#34Chlorite in the treatment of neurodegenerative disease
#35Viral chemokine-antigen fusion proteins
#36Method of treating rheumatoid arthritis with an anti-IL-6R antibody
#37Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same
#38Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
#39Methods of treatment using human antibodies that bind IL-12
#40Alteration of cell membrane for new functions
#41METHODS FOR MODULATING IL-33 ACTIVITY
#42Method of using β-hydroxy-β-methylbutyrate to treat a condition
#43METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE TO REDUCE THE RISK OF INFECTION IN AN ELDERLY INDIVIDUAL
#44METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR THE TREATMENT OF CANCER
#45Cytokine antagonists for neurological and neuropsychiatric disorders
#46PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS ASSOCIATED WITH RECEPTOR-DESENSITIZATION
#47Method of increasing immunological effect
#48Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexate
#49Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate
#50Method and composition for altering a B cell mediated pathology
#51IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS
#52CHAPERONIN 10 IMMUNOSUPPRESSION
#53MODULATION OF NKG2D
#54Method of treating rheumatoid arthritis with an anti-IL-6R antibody
#55Tacrolimus for improved treatment of transplant patients
#56Method of treating inflammatory eye disease with IL-1β binding antibodies
#57Treatment of Fibrosis related disorders
#58Therapeutic Agents
#59Compositions and methods for suppressing fibrocytes
#60IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS
#61CCI-779 concentrate formulations
#62Method of reducing pruritis using IL-31 monoclonal antibodies
#63IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS
#64Tacrolimus For Improved Treatment Of Transplant Patients
#65Solid dispersions comprising tacrolimus
#66Modified release compositions comprising tacrolimus
#67Modified release compositions comprising tacrolimus
#68Modified release compositions comprising tacrolimus
#69Modified release compositions comprising tacrolimus
#70Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders
#71Asthma Associated Factors as Targets for Treating Atopic Allergies Including Asthma and Related Disorders
#72METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY
#73Stabilized tacrolimus composition
#74Methods of Modulating Immunity
#75TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease
#76Viral chemokine-antigen fusion proteins
#77Bioactive depside and anthocyanin compounds, compositions, and methods of use
#78PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS ASSOCIATED WITH RECEPTOR-DESENSITIZATION
#79Methods of using interleukin-2 mutants with reduced toxicity
#80MODULATION OF OLIGONUCLEOTIDE CPG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
#81Chlorite in the Treatment of Neurodegenerative Disease
#82Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling
#83TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease
#84Method of treating rheumatoid arthritis with an IL-6R antibody
#85Treatment of autoimmune conditions with Copolymer 1 and related copolymers
#86Methods for treating psoriasis by administering an antibody which binds an epitope of the p40 subunit of IL-12 and/or IL-23
#87Methods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid
#88PROCESSES OF MAKING NORTH AMERICAN GINSENG FRACTIONS, PRODUCTS CONTAINING THEM, AND USE AS IMMUNOMODULATORS
#89Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
#90PEPTIDES OF IL-2
#91NOVEL RECEPTOR THAT BINDS CTLA-8
#92Treatment methods for fibrosis related disorders
#93Modulation of NKG2D
#94COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY
#95CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
#96THERAPEUTIC AGENTS
#97Compounds
#98Tacrolimus for improved treatment of transplant patients
#99Chaperonin 10 immunosuppression
#100Treatment of cancers with methylol-containing compounds and at least one electrolyte
#101Methods for human allografting
#102IL-1β binding antibodies and fragments thereof
#103Method of treating an IL-1 related coronary condition
#104STEM CELL TARGETING METHODS
#105Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
#106Solid dispersions comprising tacrolimus
#107Soluble CTLA4 mutant molecules and uses thereof
#108Therapeutic use of interleukin-2 mutants
#109HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING
#110Pharmaceutical preparations for treating inflammatory diseases
#111IL-1β binding antibodies and binding fragments thereof
#112Human Endokine Alpha and Methods of Use
#113Methods and compositions for modulating immunity
#114Methods for treating acute myeloid leukemia with diphtheria toxin-interleukin-3 conjugates
#115Interleukin-4 receptors
#116IL1-β Binding antibodies and fragments thereof
#117Methods of using IL-31 monoclonal antibodies to reduce inflammation
#118Method of treating an IL-1 related autoimmune disease or condition
#119Method of treating an IL-1 related cancer
#120ETHYLENE GLYCOL ESTERS AS PHOTOACTIVE AGENTS
#121Use of Interleukin-11 to Prevent Immune-Mediated Cytotoxicity
#122Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate
#123Human Antibodies That Bind Human IL-12 And Methods For Producing
#124USE OF TAUROLIDINE TO TREAT TUMORS
#125Method of increasing immunological effect
#126MICROENCAPSULATED MATERIALS AND METHOD OF MAKING SAME
#127Alteration of cell membrane with FasL
#128Methods of inhibiting interleukin-17 receptor
#129Use of cytokines and mitogens to inhibit graft versus host disease
#130Method of treating an IL-1 related inflammatory disease or condition
#131Method of treating or preventing an IL-1 related disease or condition
#132Antiviral activity and resolution of 2-hydroxymethyl-5(5-fluorocytosin-1-yl)-1,3-oxathiolane
#133Medium comprising chicken leukemia inhibitory factor (LIF)
#134Treatment of hematologic disorders
#135Oligonucleotides of a chicken leukemia inhibitory factor (LIF) gene
#136Method of preventing differentiation of a chicken differentiable cell using chicken leukemia inhibitory factor (LIF)
#137HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING
#138CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF
#139Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
#140Compositions and methods for WT1 specific immunotherapy
#141Methods for human allografting
#142Nucleic acid encoding human antibodies specific for interleukin 15 (IL-15)
#143Method for treating psoriasis by administering human antibodies specific for Interleukin 15 (IL-15)
#144Methods of treatment with anitbodies to a chemokine expressed in inflamed adenoid
#145Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate
#146APOPTOSIS-MIMICKING SYNTHETIC ENTITIES AND USE THEREOF IN MEDICAL TREATMENT
#147Method for preventing, or reducing the severity of, graft-versus-host disease using pluri-differentiated mesenchymal progenitor cells
#148Product and method for treatment of conditions associated with receptor-desensitization
#149IL-1β binding antibodies and fragments thereof
#150Interleukin-9 mutein peptides
#151Soluble CTLA4 mutant molecules
#152Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
#153Use of toll-like receptor-expressing cells
#154Chemically-defined non-polymeric valency platform molecules and conjugates thereof
#155Treatment for inflammatory bowel disease
#156Methods and compositions for administering stem cells
#157Methods and compositions for regenerating tissue
#158Methods and compositions for directing stem cells to the liver
#159Methods and compositions for directing stem cells to the heart
#160Apoptosis-mimicking synthetic entities and use thereof in medical treatment
#161Composition and method of treating hepatitis C
#162Methods and compositions for mobilizing stem cells
#163Ethylene glycol esters as photoactive agents
#164Heterodimeric four helix bundle cytokines
#165Method of using beta-hydroxy-beta-methylbutyrate to treat allergies and asthma
#166Herbal composition for treatment of immunocompromised conditions
#167Human interleukin-11 receptor
#168Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
#169Compositions and methods for suppressing fibrocytes
#170Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
#171Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
#172Cytokine modulators and related methods of use
#173Compositions and methods for WT1 specific immunotherapy
#174Treatment of autoimmune conditions with Copolymer 1 and related Copolymers
#175IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS
#176Heterodimeric four helix bundle cytokines
#177Methods of inhibiting an immune response with anti-human endokine alpha antibodies
#178Low dose histone peptide treatment for autoimmune disorders
#179Therapeutic use of interleukin-2 mutants
#180Modified release compositions comprising tacrolimus
#181Modulation of NKG2D for treating or preventing solid organ allograft rejection
#182Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
#183IL-31 monoclonal antibodies
#184Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
#185Very high molecular weight β-glucans
#186Chaperonin 10 immunosuppression
#187Recombinant SP-A for the treatment or prevention of pulmonary infection and inflammation
#188Eotaxin: eosinophil chemotactic cytokine
#189Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding
#190Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
#191Treatment of cancers with methylol-containing compounds and at least one electrolyte
#192Chlorite in the treatment of neurodegenerative disease
#193Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
#194Methods of treating tumors
#195Compositions and methods for WT1 specific immunotherapy
#196Pharmaceutical compositions
#197Agent for treatment of inflammatory bowel disease
#198Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate
#199Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
#200Methods for the prevention against or treatment of diabetes with ETXB and/or insulin
#201Compositions for the treatment of acquired immunodeficiency disease
#202Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
#203Use of interleukin-11 to prevent immune-mediated cytotoxicity
#204Cytokine antagonists for neurological and neuropsychiatric disorders
#205Immunotherapy of autoimmune disorders using antibodies which target B-cells
#206Cytokine modulators and related methods of use
#207Noscapine derivatives as adjuvant compositions and methods of use thereof
#208Method for inducing selected useful activities of IL-2 in a patient with peptides from IL-2
#209Use of betel leaf extract to induce IFN-gamma production from human peripheral blood T cells and as a Th1 type immunomodulator
#210Treatment for asthma
#211Anti-CD40CR MR1 antibody
#212Wound healing dressing for enhancing fibrocyte formation
#213Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
#214Method and composition for altering a B cell mediated pathology
#215Methods of suppressing fibrosis and fibrocyte formation
#216Methods for the treatment of inflammatory joint disease
#217Amino-terminally truncated rantes as chemokine antagonists
#218Antiviral activity and resolution of 2-hydroxymethyl-5- (5-fluorocytosin-1-yl)-1, 3-oxathiolane
#219Polyunsaturated fatty acid fractions of L. seeds
#220Method and composition for altering a B cell mediated pathology
#221Interleukin-2 mutants with reduced toxicity
#222Amino-terminally truncated MCP-2 as chemokine antagonists
#223Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
#224Methods of modulating immunity
#225Dipeptide apoptosis inhibitors and the use thereof
#226Immunotherapy of autoimmune disorders using antibodies which target B-cells
#227Nucleic acid encoding chicken leukemia inhibitory factor (LIF)
#228Chlorite in the treatment of neurodegenerative disease
#229Eotaxin : eosinophil chemotactic cytokine
#230Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions
#231Use of amino-terminally truncated RANTES to inhibit HIV viral replication
#232Method for administering selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS), and composition for implementing the treatment
#233Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1
#234Methods for using the obese gene and its gene product to identify hematopoietic progenitor cells
#235Methods of inducing T-cell non-responsiveness with anti-gp39 24-31 antibodies
#236Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
#237Polymorphic antiviral nucleoside compounds
#238Anti-inflammatory activity of a specific turmeric extract
#239Apoptosis-mimicking synthetic entities and use thereof in medical treatment
#240Phorboxazole derivatives for treating cancer
#241Treatment of mesothelioma
#242Antibodies to Interleukin-4 receptors and uses thereof
#243Black soybean polysaccharides
#244Method of using geranium oil and sophora root extracts as a supporting composition in cancer treatments
#245Suppression of immune response via inhibition of cathepsin S
#246Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
#247Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human
#248Therapeutic agent for a cancer and method of screening the same, and health-care auxillary food
#249Pharmaceuticals for the treatment of rejection reactions in organ transplantations
#250Suppression of immune response via inhibition of cathepsin S
#251Cytokine modulators and related method of use
#252Chlamydia protein, gene sequence and uses thereof
#2535c8 Antigen
#254Methods for inhibiting lymphotoxin β receptor signalling
#255Ethylene glycol esters as photoactive agents
#256Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
#257antigens and vaccines
#258Human antibodies that bind human IL-12